119
Participants
Start Date
August 6, 2019
Primary Completion Date
December 19, 2024
Study Completion Date
December 19, 2024
Oxytocin (OT)
During the 4 week intervention, participants will self-administer twice daily 24 International Units intranasal oxytocin (OT) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.
Placebo (P)
During the 4 week intervention, participants will self-administer twice daily 24 International Units intranasal placebo (P) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.
Department of Community Dentistry and Behavioral Science, Gainesville
UF Health of University of Florida, Gainesville
National Institute on Aging (NIA)
NIH
University of Florida
OTHER